Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine

Cardiovascular Drugs and Therapy

Volumn 20, Issue 5, 2006, Pages 327-334

  Use, Tadasuke ^a   Makita, Tetsuji ^a   Ureshino, Hiroyuki ^a   Cho, Sungsam ^a   Yoshitomi, Osamu ^a   Akiyama, Daiji ^a   Oshibuchi, Motoko ^a   Hara, Tetsuya ^a   Sumikawa, Koji ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Ischemia; Milrinone; Myocardial stunning; Reperfusion; Swine

Indexed keywords

LIDOCAINE; MILRINONE; SODIUM CHLORIDE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE FIBRILLATION; INFUSION RATE; LOADING DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUNNED HEART MUSCLE; SWINE; TACHYCARDIA;

ANESTHESIA; ANIMALS; CARDIOTONIC AGENTS; FEMALE; MALE; MILRINONE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL STUNNING; PHOSPHODIESTERASE INHIBITORS; SWINE;

EID: 33845677585     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-0166-7     Document Type: Article

References (36)

1. Evans DB. Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors. Am J Cardiol 1989;63:9A-11A.
2. Colucci WS. Cardiovascular effects of milrinone. Am Heart J 1991;121:1945-7.
3. Metra M, Nodari S, D'Aloia A et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol and carvedilol. J Am Coll Cardiol 2002;40:1248-58.
4. Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002;73:325-30.
5. Schwinn DA, Leone BJ, Spahn DR et al. Desensitization of myocardial beta-adrenergic receptors during cardiopulmonary bypass. Evidence for early uncoupling and late downregulation. Circulation 1991;84:2559-67.
6. Sanada S, Kitakaze M, Papst PJ et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 2001;104:705-10.
7. Nomura Y, Horimoto H, Mieno S et al. Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction. Mol Cell Biochem 2003;248:179-84.
8. Saltman AE, Gaudette GR, Levitsky S, Krukenkamp IB. Amrinone preconditioning in the isolated perfused rabbit heart. Ann Thorac Surg 2000;70:609-13.
9. Kim SJ, Depre C, Vatner SF. Novel mechanisms mediating stunned myocardium. Heart Fail Rev 2003;8:143-53.
10. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation 2001;104:2981-9.
11. Grubitzsch H, Ansorge K, Wollert HG, Eckel L. Stunned myocardium after off-pump coronary artery bypass grafting. Ann Thorac Surg 2001;71:352-5.
12. Ruiz-Bailen M, Aguayo de Hoyos E, Ruiz-Navarro S et al. Reversible myocardial dysfunction after cardiopulmonary resuscitation. Resuscitation 2005;66:175-81.
13. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and cellular implication of stunning, hibernation, and preconditioning; an NHLBI work shop. Circulation 1998;97:1848-67.
14. Vinten-Johansen J, Zhao ZQ, Zatta AJ, Kin H, Halkos ME, Kerendi F. Postconditioning - a new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol 2005;100:295-310.
15. Halkos ME, Kerendi F, Corvera JS et al. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 2004;78:961-9.
16. Zhao ZQ, Corvera JS, Wang N-P et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-88.
17. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cellsurvival signaling. Circ Res 2001;89:1191-8.
18. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508-15.
19. Toller WG, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning. Anesthesiology 1999;91:1437-46.
20. Peart JN, Gross ER, Gross GJ. Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol 2005;42:211-8.
21. Weihrauch D, Krolikowski JG, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS. Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesth Analg 2005;101:942-9.
22. Piper HM, Abdallah Y, Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 2004;61:365-71.
23. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-34.
24. Kikura M, Sato S. The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg 2002;94:22-30.
25. Lobato EB, Florete O Jr, Bingham HL. A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. Br J Anaesth 1998;81:782-4.
26. Hamada Y, Kawachi K, Yamamoto T et al. Effects of single administration of phosphodiesterase III inhibitor during cardiopulmonary bypass: comparison of milrinone and amrinone. Jpn Circ J 1999;63:605-9.
27. Schad H, Heimisch W, Eising GP, Mendler N. Effect of milrinone and atrial pacing on stunned myocardium. Eur J Cardiothorac Surg 1997;6:1125-32.
28. Vandeplassche GM, Hermans CF, de Chaffoy de Courcelles DR, D'Aubioul JA, Wouters LJ, De Clerck FF. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs. J Cardiovasc Pharmacol 1992;19:714-22.
29. Alousi AA, Iwan T, Edelson J, Biddlecome C. Correlation of the hemodynamic and pharmacokinetic profile of intravenous milrinone in the anesthetized dog. Arch Int Pharmacodyn Ther 1984;267:59-66.
30. Kikura M, Levy JH, Michelsen LG et al. The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. Anesth Analg 1997;85:16-22.
31. Rump AF, Acar D, Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 1994;112:757-62.
32. Rump AF, Schussler M, Acar D et al. Effects of different inotropes with antioxidant properties on acute regional myocardial ischemia in isolated rabbit hearts. Gen Pharmacol 1995;26:603-11.
33. Ytrehus K. The ischemic heart-experimental models. Pharmacol Res 2000;42:193-203.
34. Stump GL, Wallace AA, Gilberto DB, Gehret JR, Lynch JJ Jr. Arrhythmogenic potential of positive inotropic agents. Basic Res Cardiol 2000;95:186-98.
35. Hanich RF, Levine JH, Prood C et al. Electrophysiologic recovery in postischemic, stunned myocardium despite persistent systolic dysfunction. Am Heart J 1993;125:23-32.
36. Stevens RM, Jahania MS, Mentzer RM, Lasley RD. Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardial stunning. Ann Thorac Surg 2004;77:651-7.